Compare ANL & CTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANL | CTY |
|---|---|---|
| Founded | 2004 | 2023 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 998.8M | 1.0B |
| IPO Year | 2022 | 2026 |
| Metric | ANL | CTY |
|---|---|---|
| Price | $10.80 | $17.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $29.50 | ★ $37.33 |
| AVG Volume (30 Days) | ★ 268.1K | 238.1K |
| Earning Date | 08-14-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $243.83 | $62.96 |
| Revenue Next Year | N/A | $7.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $15.81 |
| 52 Week High | $17.25 | $22.65 |
| Indicator | ANL | CTY |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 39.86 |
| Support Level | $8.95 | $16.01 |
| Resistance Level | $11.90 | $21.98 |
| Average True Range (ATR) | 0.99 | 2.22 |
| MACD | 0.25 | -0.20 |
| Stochastic Oscillator | 72.55 | 23.83 |
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.